Analyst sees higher ad revenue per daily active user growth ahead for Snap and attractive valuation.
Analyst nearly doubles price target between Gocovri pricing and better prospects in Multiple Sclerosis arena.
Analyst bumps up price target on QDEL on back of “sweetened” deal to acquire Alere’s BNP Assay segment.
Analyst lifts price target on Oncolytics with new clarity from the FDA on Reolysin’s path forward to approval.
Analyst spotlights a compelling path forward for DMD program and looks to key catalysts in fourth quarter.
Forecasting a potential $500 million yearly sales opportunity ahead, the analyst lifts price target on Array.
Liana Moussatos Joins A Slew of Analysts That Are Gaining More Confidence in Xoma
Momo’s Content to Bring New Users to the Table and Boost Current User Engagment
On the heels of a solid fiscal first quarter beat from Alibaba Group Holding Ltd (NYSE:BABA), analyst Jason Helfstein of Oppenheimer is becoming …
Mark Mahaney of RBC Capital rates stocks in the internet sector and is one of the top 20 analysts rated on TipRanks. Yesterday, Mahaney …
